Literature DB >> 19896448

Production of pharmaceutical-grade plasmids at high concentration and high supercoiled percentage.

Ying Cai1, Stephen Rodriguez, Ramu Rameswaran, Ruxandra Draghia-Akli, Robert J Juba, Henry Hebel.   

Abstract

The increased use of plasmid-based vaccines to replace their more challenging viral counterparts has increased the demand for high purity and high concentration plasmids. Here we report the production of plasmids encoding different transgenes for DNA vaccine candidates at gram scale with an integrated process consisting of batch fermentation and limited steps of purification. Plasmid products encoding for eight smallpox antigens that were combined into a bioterrorism DNA vaccine exhibited high purity with undetectable RNA, protein and endotoxin, concentration of up to 13.6mg/mL and supercoiled percentage of 94.5+/-1.1% after storage at -80 degrees C for over 1 year. The process has been scaled up for the cGMP manufacture of pharmaceutical-grade human papillomavirus and influenza DNA vaccines up to a 50g scale, also demonstrating high purity and high concentration. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896448     DOI: 10.1016/j.vaccine.2009.10.057

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.

Authors:  Jay R McCoy; Janess M Mendoza; Kristin W Spik; Catherine Badger; Alan F Gomez; Connie S Schmaljohn; Niranjan Y Sardesai; Kate E Broderick
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine.

Authors:  Jian Yan; Daniel O Villarreal; Trina Racine; Jaemi S Chu; Jewell N Walters; Matthew P Morrow; Amir S Khan; Niranjan Y Sardesai; J Joseph Kim; Gary P Kobinger; David B Weiner
Journal:  Vaccine       Date:  2014-03-12       Impact factor: 3.641

3.  Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process.

Authors:  Jared Nelson; Stephen Rodriguez; Neil Finlayson; Jim Williams; Aaron Carnes
Journal:  Hum Vaccin Immunother       Date:  2013-07-30       Impact factor: 3.452

4.  Toward QbD Process Understanding on DNA Vaccine Purification Using Design of Experiment.

Authors:  Lalintip Hocharoen; Sarawuth Noppiboon; Panit Kitsubun
Journal:  Front Bioeng Biotechnol       Date:  2021-05-12

Review 5.  Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy.

Authors:  Toshiharu Hayashi
Journal:  J Biomed Biotechnol       Date:  2010-08-17

6.  A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.

Authors:  Jay R McCoy; Janess M Mendoza; Kristin W Spik; Catherine Badger; Alan F Gomez; Connie S Schmaljohn; Niranjan Y Sardesai; Kate E Broderick
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.